US 8283309
Bridged carbocyclic oxime hepatitis C virus serine protease inhibitors
granted A61PA61P31/12
Quick answer
US patent 8283309 (Bridged carbocyclic oxime hepatitis C virus serine protease inhibitors) held by Enanta Pharmaceuticals, Inc. expires Mon Oct 04 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Enanta Pharmaceuticals, Inc.
- Grant date
- Tue Oct 09 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 04 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61P, A61P31/12